-
In response to the national influenza vaccine shortage, the Centers for Disease Control and Prevention is providing the answers to some of the most common questions by clinicians and the public.
-
The loss of roughly half the nations flu vaccine supply for the 2004-2005 season has infection control professionals scrambling to revamp their programs and secure adequate doses for health care workers and high-risk patients.
-
A novel influenza vaccine plagued by so much controversy the manufacturer almost gave up making it now is considered a good option for many health care workers during this seasons vaccine shortage, public health officials advise.
-
-
-
MediGene AG has initiated a clinical Phase I/II trial of the drug candidate NV1020 for the treatment of liver metastases developing from colorectal cancer.
-
Part 1 of 2: Indications, Mechanism of Action, Pharmacokinetics, Dosing & Administration, Adverse Events, amd Interactions. Cinacalcet is the first in a class of calcimimetic agents that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium.
-
Hydromorphone hydrochloride (Palladone); New indication for duloxetine hydrochloride (Cymbalta).
-
Rofecoxib, celecoxib (Celebrex), and valdecoxib (Bextra) are a subclass of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively block the enzyme COX-2 (cyclooxygenase-2). When Merck announced the rofecoxib withdrawal, it said that its study results were not necessarily applicable to others in the COX-2 inhibitor class.
-
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.
